Quantum BioPharma Hits Midpoint Enrollment in MS Imaging Study, Signaling Potential for Novel Diagnostic and Therapeutic Advances
Quantum BioPharma announced that its collaborative MS imaging study with Massachusetts General Hospital has reached midpoint enrollment, with preliminary PET tracer data showing promise for detecting active and gray matter lesions, which could accelerate development of its investigational MS therapy Lucid-MS.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced on May 19, 2026, that patient enrollment in its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached the halfway mark. Preliminary imaging data from the study show encouraging signals in acute MS lesions and potential sensitivity to gray matter lesions, according to the company. The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination, which could enhance the development of MS therapies, including Quantum's investigational candidate Lucid-MS.
This milestone is significant because it brings the study closer to validating a non-invasive method to visualize myelin damage in real time, a critical need in MS diagnosis and treatment monitoring. Current imaging tools often miss gray matter lesions, which are associated with disability progression. If successful, the [¹⁸F]3F4AP tracer could become a standard tool for assessing demyelination, potentially accelerating clinical trials for remyelinating therapies.
Quantum's lead compound, Lucid-MS, is a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical models. The company submitted an Investigational New Drug (IND) application for a Phase 2 trial of Lucid-MS to the FDA in March 2026. The imaging study's results could provide crucial biomarkers to evaluate Lucid-MS's efficacy in human trials.
The company also retains a stake in Unbuzzd Wellness Inc., which markets UNBUZZD, an over-the-counter product for alcohol misuse. Quantum owns 19.84% of Unbuzzd as of March 31, 2026, and receives royalty payments of 7% of sales until $250 million is paid, after which the royalty drops to 3% in perpetuity. This provides a potential revenue stream independent of its pharmaceutical pipeline.
Quantum BioPharma is dedicated to building a portfolio of innovative biotech solutions for neurodegenerative, metabolic, and alcohol misuse disorders. The company's progress in the MS imaging study and the pending Phase 2 trial for Lucid-MS represent key steps toward addressing unmet needs in multiple sclerosis treatment. For more details, the full press release is available at https://ibn.fm/4IZ0y. Updates on QNTM can be found in the company's newsroom at https://ibn.fm/QNTM.